Medicare Part D

How Medicare Part D approaches GLP-1 coverage

Medicare Part D coverage of GLP-1 receptor agonists turns on the prescribed indication, not the molecule. Under SSA §1860D-2(e)(2)(A), drugs used for weight loss are statutorily excluded — Wegovy or Zepbound prescribed for obesity alone cannot be covered by any Part D plan. The critical 2024 development: when a GLP-1 carries a separate non-weight-loss FDA indication (Wegovy's cardiovascular risk reduction via the SELECT trial; Zepbound's moderate-to-severe obstructive sleep apnea in adults with obesity), individual Part D plans may choose to cover the drug for that specific indication. Coverage remains plan-by-plan, typically requires prior authorization, step therapy, and indication-specific documentation, and is not guaranteed on every formulary. T2D-indicated GLP-1s (Ozempic, Mounjaro, Rybelsus) are generally covered when prescribed for type 2 diabetes with documentation, though tier, quantity limits, and PA requirements vary. Verify with your specific plan and current year formulary.

Statutory and structural notes

Social Security Act §1860D-2(e)(2)(A), enacted via the Medicare Modernization Act of 2003, excludes "agents when used for anorexia, weight loss, or weight gain" from Part D coverage. The exclusion applies to indication, not molecule — a GLP-1 with a separate non-weight-loss FDA indication may be covered when prescribed for that indication, subject to plan formulary. The Treat and Reduce Obesity Act (TROA) would amend this exclusion but has not been enacted as of 2026.

Typically considered for coverage

The list below reflects general patterns observed across Medicare Part Dplan documents. Coverage for any specific drug, dose, or indication must be confirmed against your own plan's current formulary and medical policy.

• Ozempic (semaglutide) when prescribed for type 2 diabetes with documentation — coverage, tier, and PA requirements vary by plan; verify with your specific plan and current year formulary
• Mounjaro (tirzepatide) when prescribed for type 2 diabetes with documentation — coverage and PA requirements vary by plan; verify with your specific plan and current year formulary
• Rybelsus (oral semaglutide) when prescribed for type 2 diabetes with documentation — coverage varies by plan; verify with your specific plan and current year formulary
• Wegovy (semaglutide) may be covered under Part D plans that have chosen to include it on formulary for the FDA-approved cardiovascular risk reduction indication (established CVD + overweight/obesity) following the 2024 SELECT-based label update; coverage is plan-specific and not guaranteed — verify with your specific plan and current year formulary
• Zepbound (tirzepatide) may be covered under Part D plans that have chosen to include it on formulary for the FDA-approved moderate-to-severe obstructive sleep apnea indication in adults with obesity (2024 label update); coverage is plan-specific and not guaranteed — verify with your specific plan and current year formulary

Typically excluded

• Any GLP-1 prescribed solely for weight loss or chronic weight management — statutorily excluded under SSA §1860D-2(e)(2)(A)
• Wegovy prescribed for obesity without the cardiovascular risk reduction indication
• Zepbound prescribed for obesity without the obstructive sleep apnea indication
• Saxenda (liraglutide) prescribed for weight management — no separate non-weight-loss indication exists for this product
• Off-label weight-loss use of Ozempic, Mounjaro, or Rybelsus in patients without documented type 2 diabetes
• Compounded semaglutide or tirzepatide — generally not covered by Part D

Prior authorization

Prior authorization is commonly required for GLP-1 medications under Medicare Part D plans. Your prescriber typically submits a PA form with diagnosis codes, lab results (e.g., A1c for T2D, BMI for weight management), documented prior therapy attempts, and clinical justification.

Appeal strategy if denied

Part D appeals follow a 5-level process: plan redetermination (within 60 days of denial), Independent Review Entity reconsideration, ALJ hearing, Medicare Appeals Council, then federal court. For GLP-1 denials, appeals must show the prescription is for a covered indication (T2D, CV risk reduction, or OSA) — not weight loss. Submit chart notes with qualifying ICD-10 codes and FDA-approved indication language. Statutory weight-loss denials cannot be overcome on medical-necessity grounds.

GLP1Zoom is not an insurance company, broker, or health plan. We summarize general payer patterns from public plan documents and statute to help you ask the right questions. Always verify current coverage with your plan's member services. Full disclaimer.